JPRN-UMIN000002972已完成2 期
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma - Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Massive pleural or abdominal effusion 2)Uncontrolled hypertension 3)Uncontrolled heart disease 4)Evidence of Myocardial infarction witin 6 months 5)Active infection (except viral hepatitis) 6)Active gastrointestinal bleeding or ulcer 7)active double cancer 8)encephalopacy or severe mental disorder 9)severe drug allergy 10)pregnancy or lactaing females 11)inadequate for administration orally 12)Inadequate physical condition,as diagnosed by primary physician
研究者
相似试验
已完成
2 期
Phase II study of sorafenib with S-1 for advanced hepatocellular carcinoma.Hepatocellular carcinomaJPRN-UMIN000007199Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University25
进行中（未招募）
1 期
A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic CarcinomaEUCTR2008-000066-22-GBChristie Hospital NHS Foundation Trust
进行中（未招募）
不适用
Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older - Sorafenib in Child Pugh Score B patientshepatocellular carcinoma and Child Pugh score BMedDRA version: 9.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableEUCTR2008-008232-87-DECharite Universitätsmedizin Berlin- Campus Virchow-Klinikum
招募中
2 期
Phase II study of sorafenib-regorafneib sequential therapy for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190082Yamashita Tatsuya33
进行中（未招募）
不适用
Phase II single agent sorafenib in the treatment of relapsed oesophageal/gastric adenocarcinoma in platinum pre-treated patients - Sorafenib upper GI studyEUCTR2008-005062-31-IEICORG, the all-Ireland Co-operative Oncology Research Group54